CONSHOHOCKEN, PA--(Marketwire - Nov 2, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced the appointment of Bart J. Dunn as vice president of corporate development and licensing.

Mr. Dunn is an accomplished biopharmaceutical executive, with more than 20 years of industry experience at both large and small life science companies. He has a strong and diverse background with past roles in strategic planning, business development, corporate development, licensing and financial operations. Prior to joining NuPathe, Mr. Dunn served as vice president, business development and strategic planning at Inspire Pharmaceuticals, where he led the company's corporate development, licensing and strategic planning efforts, culminating in the successful sale of Inspire to Merck earlier this year. Prior to Inspire, Mr. Dunn served in various business development and strategic planning roles at Pfizer.

"We are very excited to have someone of Bart's caliber and expertise join our team at this critical juncture in the growth of the company," said [ Jane H. Hollingsworth ], chief executive officer. "As we ready our migraine patch for approval and launch, we are increasingly outwardly focused, seeking to create additional value from our products and technologies. Bart's deep experience in pharmaceutical licensing and business development will be a great asset as we pursue these opportunities."

In his new role, Mr. Dunn assumes all corporate development and licensing responsibilities for the company, including those held by [ Ezra Felker ], who recently assumed new responsibilities at NuPathe as vice president of manufacturing operations.

About NuPathe
NuPathe Inc. ([ www.nupathe.com ]) is an emerging pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to the Company's expectations, plans and beliefs regarding: the approval and launch of NP101; licensing and business development opportunities; and partnering of NP201. Forward-looking statements are based upon management's current expectations, plans and beliefs and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from those indicated herein including, among others: NuPathe's ability to address the questions raised by the FDA in its Complete Response Letter regarding NuPathe's New Drug Application for NP101; varying interpretation of study data; NuPathe's ability to obtain additional financing; and the risks, uncertainties and other factors discussed in NuPathe's Annual Report on Form 10-K for the year ended December 31, 2010 and in NuPathe's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 under the caption "Risk Factors" and elsewhere in such reports, which are available on NuPathe's website at [ www.nupathe.com ] in the "Investor Relations -- SEC Filings" section. While NuPathe may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.